期刊文献+

Maresin-1对脓毒症器官保护作用的研究进展

Research progress on the organ-protective effect of Maresin-1 in sepsis
原文传递
导出
摘要 脓毒症是宿主对感染产生的炎症反应失控而导致的致命性器官功能障碍。过度炎症反应是脓毒症发生发展的核心环节,器官功能损伤程度与脓毒症预后直接相关,及时干预过度炎症反应、缓解器官功能损伤是改善脓毒症预后的关键。Maresin-1(MaR-1)是一种新近发现的内源性特异性促炎症消退介质,可在脓毒症中发挥抗炎、促炎症消退及器官保护作用,可能是脓毒症治疗的新靶点。本文就MaR-1参与脓毒症炎症调控的机制及其器官保护作用的相关研究进展进行综述,以期为临床研发新的脓毒症治疗药物提供参考依据。 Sepsis is a fatal organ dysfunction caused by the uncontrolled inflammatory response of the host to infection.Excessive inflammatory reaction is the core factor in the occurrence and development of sepsis,the degree of organ dysfunction is directly related to the prognosis of sepsis.Timely intervention of excessive inflammatory response and alleviation of organ function damage are essential to improve the prognosis of sepsis.Maresin-1(MaR-1)is a newly discovered endogenous specific pro-inflammatory resolution mediator,which plays a role of anti-inflammatory,pro-inflammatory regression and organ protection in sepsis,and may be a new target for the treatment of sepsis.This article reviews the research progress of the role of MaR-1 in the regulation of inflammation and organ protection in sepsis,in order to provide reference for the clinical development of new drugs for the treatment of sepsis.
作者 唐立丽 龚模祥 陈荍 苏志勇 李小悦 Tang Lili;Gong Moxiang;Chen Qiao;Su Zhiyong;Li Xiaoyue(Department of Critical Care Medicine,the Fifth Affiliated(Zhuhai)Hospital of Zunyi Medical University,Zhuhai 519100,Guangdong,China)
出处 《中华危重病急救医学》 CAS CSCD 北大核心 2024年第2期211-215,共5页 Chinese Critical Care Medicine
基金 国家自然科学基金(81960361) 广东省医学科学技术研究项目(B2023238)。
关键词 Maresin-1 脓毒症 脓毒症相关性器官损伤 过度炎症反应 Maresin-1 Sepsis Sepsis-associated organ injury Excessive inflammatory reaction
  • 相关文献

参考文献11

二级参考文献87

  • 1余晨,刘志红,陈朝红,龚德华,季大玺,黎磊石.连续性血液净化对血浆细胞因子水平的影响及其清除机制[J].肾脏病与透析肾移植杂志,2004,13(5):401-407. 被引量:68
  • 2杨从山,邱海波,刘松桥,杨毅,黄英姿,刘玲.血管外肺水指数对感染性休克患者预后的评价[J].中华内科杂志,2006,45(3):192-195. 被引量:53
  • 3季大玺,陶静.急性肾损伤与连续性血液净化[J].中国血液净化,2006,5(12):819-821. 被引量:14
  • 4COHEN J. The immunopathogenesis of sepsis[J]. Nature, 2002, 420(6917): 885-891.
  • 5ANGUS D C, VANDER P T. Severe sepsis and septic shock [J]. N Engl J Med, 2013, 369(21): 2063.
  • 6VANDENBERG J W, VANDERZEE M, DEBRUIN R W,et al. Mild versus strong anti-inflammatory therapy during early sepsis in mice: a matter of life and death[J]. Crit Care Meal, 2011, 39(6): 1275-1281.
  • 7FISHER C J, DHAINAUT J F, OPAL S M, et al. Recombi- nant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase Ⅲ rhlL-lra Sepsis Syndrome Study Group[J]. JAMA, 1994, 271(23): 1836-1843.
  • 8OPAL S M, LATERRE P F, FRANCOIS B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in pa- tients with severe sepsis: the ACCESS randomized trial[J]. JAMA, 2013, 309(11): 1154-1162.
  • 9SERHAN C N. Resolution phase of inflammation: novel en- dogenous anti-inflammatory and proresolving lipid mediators and pathways[J]. Annu Rev Immunol, 2007, 25: 101-137.
  • 10SERHAN C N, YANG R, MARTINOD K, et al. Maresins: novel macro-phage mediators with potent anti-inflammatory and proresolving actions[J]. J Exp Med, 2009, 206(1): 15- 23.

共引文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部